Fatty‐acid metabolism and the pathogenesis of hepatocellular carcinoma: Review and hypothesis

Despite increasing understanding of the genetic control of cell growth and the identification of several involved chemical and infectious factors, the pathogenesis of clinical and experimental hepatocellular carcinoma remains unknown. Available evidence is consistent with the possibility that selected changes in the hepatocellular metabolism of long‐chain fatty acids may contribute significantly to this process. Specifically, studies of the peroxisome proliferators, a diverse group of xenobiotics that includes the fibrate class of hypolipidemic drugs, suggest that increased fatty acid oxidation by way of extramitochondrial pathways (i.e.,‐oxidation in the smooth endoplasmic reticulum and β‐oxidation in the peroxisomes) results in a corresponding increase in the generation of hydrogen peroxide and, thus, oxidative stress. This in turn leads to alterations in gene expression and in DNA itself. We also review evidence supporting a potentially decisive influence of particular aspects of hepatocellular fatty acid metabolism in determining the activity of the extramitochondrial pathways. Moreover, certain intermediates of extramitochondrial fatty acid oxidation (e.g., the long‐chain dicarboxylic fatty acids) impair mitochondrial function and are implicated as modulators of gene expression through their interaction with the peroxisome proliferator‐activated receptor. Finally, the occurrence of hepatic tumors in type I glycogen storage disease (glucose‐6‐phosphatase deficiency) may exemplify this general mechanism, which may also contribute to nonneoplastic liver injury and to tumorigenesis in other tissues. (HEPATOLOGY 1993;18:669–676.)

[1]  J Milner,et al.  A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. , 1993, Cancer research.

[2]  Barry Halliwell,et al.  DNA damage by oxygen‐derived species Its mechanism and measurement in mammalian systems , 1991, FEBS letters.

[3]  T. Goldsworthy,et al.  Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. , 1992, Carcinogenesis.

[4]  P. Ortiz de Montellano,et al.  Induction of peroxisomal fatty acid beta-oxidation and liver fatty acid-binding protein by peroxisome proliferators. Mediation via the cytochrome P-450IVA1 omega-hydroxylase pathway. , 1993, The Journal of biological chemistry.

[5]  M. Rao,et al.  Induction of rat liver DNA alterations by chronic administration of peroxisome proliferators as detected by 32P-postlabeling. , 1991, Mutation research.

[6]  T. Rushmore,et al.  The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. , 1991, The Journal of biological chemistry.

[7]  J. Reddy,et al.  Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. , 1989, Cancer research.

[8]  I. Issemann,et al.  A role for fatty acids and liver fatty acid binding protein in peroxisome proliferation? , 1992, Biochemical Society transactions.

[9]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[10]  D. Crane,et al.  Identification of a catalase-negative sub-population of peroxisomes induced in mouse liver by clofibrate. , 1991, Biochimica et biophysica acta.

[11]  C. Bréchot,et al.  Persistence of Hepatitis B and Hepatitis C Viral Genomes in Primary Liver Cancers from HBsAg‐Negative Patients: A Study of a Low‐endemic Area , 1993, Hepatology.

[12]  P. Tsichlis,et al.  Liver fatty acid binding protein is the mitosis-associated polypeptide target of a carcinogen in rat hepatocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Okuda,et al.  Hepatocellular carcinoma: Recent progress , 1992, Hepatology.

[14]  D. Laskin Nonparenchymal Cells and Hepatotoxicity , 1990, Seminars in liver disease.

[15]  N. Iritani Nutritional and hormonal regulation of lipogenic-enzyme gene expression in rat liver. , 1992, European journal of biochemistry.

[16]  M. Rao,et al.  An overview of peroxisome proliferator-induced hepatocarcinogenesis. , 1991, Environmental health perspectives.

[17]  P. Eacho,et al.  Inhibition of hepatic fatty acid oxidation at carnitine palmitoyltransferase I by the peroxisome proliferator 2-hydroxy-3-propyl-4-[6-(tetrazol-5-yl) hexyloxy]acetophenone. , 1988, The Biochemical journal.

[18]  J. Vamecq,et al.  Peroxisomal and mitochondrial beta-oxidation of monocarboxylyl-CoA, omega-hydroxymonocarboxylyl-CoA and dicarboxylyl-CoA esters in tissues from untreated and clofibrate-treated rats. , 1989, Journal of biochemistry.

[19]  N. Fausto,et al.  Mechanisms of growth regulation in liver regeneration and hepatic carcinogenesis. , 1993, Progress in liver diseases.

[20]  P. Eacho,et al.  Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883. , 1991, Carcinogenesis.

[21]  N. Bass,et al.  Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation. , 1990, Biochimica et biophysica acta.

[22]  G. F. Gates,et al.  Scintigraphic abnormalities in glycogen storage disease. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  B. Lake,et al.  Microsomal cytochrome P-452 induction and peroxisome proliferation by hypolipidaemic agents in rat liver. A mechanistic inter-relationship. , 1988, Biochemical pharmacology.

[24]  B Beije,et al.  On the mechanism of the hepatocarcinogenicity of peroxisome proliferators. , 1991, Chemico-biological interactions.

[25]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Leonard,et al.  Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Suga,et al.  Induction of peroxisomal β-oxidation enzymes by dehydroepiandrosterone and its sulfate in primary cultures of rat hepatocytes , 1992 .

[28]  R. Wanders,et al.  Biochemistry of peroxisomes. , 1992, Annual review of biochemistry.

[29]  K. Andersson,et al.  The effects of perfluoro-octanoic acid on hepatic peroxisome proliferation and related parameters show no sex-related differences in mice. , 1992, The Biochemical journal.

[30]  R. Stevenson,et al.  Hepatic adenomata with type 1 glycogen storage disease. , 1976, JAMA.

[31]  H. Greene,et al.  Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. , 1981, Gastroenterology.

[32]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[33]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[34]  T. Aoyama,et al.  Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the omega- and (omega-1)-hydroxylation of fatty acids and the omega-hydroxylation of prostaglandins E1 and F2 alpha. , 1990, Journal of lipid research.

[35]  D. Waxman,et al.  Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. Male specificity of liver and kidney CYP4A2 mRNA and tissue-specific regulation by growth hormone and testosterone. , 1992, The Journal of biological chemistry.

[36]  R. Coleman,et al.  Hepatic ultrasonography in type I glycogen storage disease (von Gierke disease). Detection of hepatic adenoma and carcinoma. , 1981, Radiology.

[37]  A. Muerhoff,et al.  The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. , 1992, The Journal of biological chemistry.

[38]  N. Bass,et al.  Fatty acid binding proteins: recent concepts of regulation and function. , 1992, Progress in clinical and biological research.

[39]  S. Sorof,et al.  Preferential binding of growth inhibitory prostaglandins by the target protein of a carcinogen. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T. Nicotera Molecular and biochemical aspects of Bloom's syndrome. , 1991, Cancer genetics and cytogenetics.

[41]  L. Loeb,et al.  8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. , 1992, The Journal of biological chemistry.

[42]  M J Holness,et al.  Hepatic carbon flux after re-feeding in the glycogen-storage-disease (gsd/gsd) rat. , 1987, The Biochemical journal.

[43]  U. K. Misra,et al.  Chronic ethanol treatment induces H2O2 production selectively in pericentral regions of the liver lobule. , 1992, Alcoholism: Clinical and Experimental Research.

[44]  J. McGarry,et al.  Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase. , 1989, Diabetes/metabolism reviews.

[45]  P. Marion,et al.  Hepadnaviruses and hepatocellular carcinoma. , 1991, Annual review of microbiology.

[46]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[47]  D. Ganem Of marmots and men , 1990, Nature.

[48]  J. Gustafsson,et al.  Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Green Peroxisome proliferators: a model for receptor mediated carcinogenesis. , 1992, Cancer surveys.

[50]  J. Gollan,et al.  Sex differences in hepatic uptake of long chain fatty acids in single-pass perfused rat liver. , 1981, Journal of lipid research.

[51]  T. Ono,et al.  Immunohistochemical demonstration of liver fatty acid‐binding protein in human hepatocellular malignancies , 1990, The Journal of pathology.

[52]  M. Thomassen,et al.  Induction of peroxisomal beta-oxidation in rat liver by high-fat diets. , 1980, The Biochemical journal.

[53]  G. Getz,et al.  Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria. , 1985, The Journal of clinical investigation.

[54]  J. Gustafsson,et al.  Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Buchwald,et al.  Molecular and Cellular Biology of Fanconi Anemia , 1992, The American journal of pediatric hematology/oncology.

[56]  S. Iseki,et al.  Light microscopic localization of hepatic fatty acid binding protein mRNA in jejunal epithelia of rats using in situ hybridization, immunohistochemical, and autoradiographic techniques. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[57]  C. Lieber,et al.  Hepatotoxicity of ethanol. , 1991, Journal of hepatology.

[58]  N. Kemeny,et al.  Type la glycogenosis associated with hepatocellular carcinoma , 1992 .

[59]  C. Stanley,et al.  Inherited disorders of mitochondrial fatty acid oxidation. , 1992, Progress in liver diseases.

[60]  J. Capone,et al.  Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  T. Ono,et al.  Immunocytochemical localization of hepatic fatty acid binding protien in the rat intestine: Effect of fasting , 1989, The Anatomical record.

[62]  R. Schulte‐Hermann,et al.  Role of oxidative stress in age dependent hepatocarcinogenesis by the peroxisome proliferator nafenopin in the rat. , 1991, Cancer research.

[63]  G. Michalopoulos,et al.  Plasma levels of HGF in rats treated with tumor promoters. , 1992, Carcinogenesis.

[64]  C. B. Pickett,et al.  Regulation of rat glutathione S-transferase Ya subunit gene expression. DNA-protein interaction at the antioxidant responsive element. , 1992, The Journal of biological chemistry.

[65]  A. Beaudet,et al.  Glycogen storage disease: long‐term follow‐up of nocturnal intragastric feeding , 1982, Clinical genetics.

[66]  H. Greene,et al.  Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease. , 1976, The New England journal of medicine.

[67]  G. Michalopoulos,et al.  Hepatocyte growth factor , 1992, Hepatology.

[68]  P. Eacho,et al.  Inhibition of hepatic fatty acid oxidation by bezafibrate and bezafibroyl CoA. , 1988, Biochemical and biophysical research communications.

[69]  O. Mamer,et al.  Urinary excretion of C6-C10 dicarboxylic acids in glycogen storage disease types I and 3. , 1974, Clinica chimica acta; international journal of clinical chemistry.

[70]  J. D. Frank,et al.  Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. , 1992, Toxicology and applied pharmacology.

[71]  C. Barker,et al.  Specific growth stimulation by linoleic acid in hepatoma cell lines transfected with the target protein of a liver carcinogen. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  N. Bass,et al.  Light microscopic immunocytochemical localization of hepatic and intestinal types of fatty acid-binding proteins in rat small intestine. , 1986, Journal of lipid research.

[73]  B. Ames,et al.  Normal oxidative damage to mitochondrial and nuclear DNA is extensive. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[74]  B. Ames,et al.  Chemical carcinogenesis: too many rodent carcinogens. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[75]  J. Pignon,et al.  Gender Differences in the Response of Hepatic Fatty Acids and Cytosolic Fatty Acid-Binding Capacity to Alcohol Consumption in Rats , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[76]  L. Ellwein,et al.  Cell proliferation in carcinogenesis. , 1990, Science.

[77]  M. Rao,et al.  Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. , 1989, Mutation research.

[78]  F. Ponchel,et al.  p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. , 1993, Oncogene.

[79]  J. Popp,et al.  Role of fatty acyl coenzyme A oxidase in the efflux of oxidized glutathione from perfused livers of rats treated with the peroxisome proliferator nafenopin. , 1987, Cancer research.

[80]  B. Lake,et al.  Hepatic peroxisome proliferation and oxidative stress. , 1990, Biochemical Society transactions.

[81]  T. Curran,et al.  Redox regulation of fos and jun DNA-binding activity in vitro. , 1990, Science.

[82]  S. Monroe,et al.  Sex steroid modulation of fatty acid utilization and fatty acid binding protein concentration in rat liver. , 1980, The Journal of clinical investigation.

[83]  R. Custer,et al.  Mitosis in hepatocytes is generally associated with elevated levels of the target polypeptide of a liver carcinogen. , 1985, Differentiation; research in biological diversity.

[84]  R. Melnick Does chemically induced hepatocyte proliferation predict liver carcinogenesis? , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  E. Jellum,et al.  The occurrence of adipic and suberic acid in urine from ketotic patients. , 1972, Clinica chimica acta; international journal of clinical chemistry.

[86]  C. Boland,et al.  Fiber and colon cancer: the weight of the evidence. , 1992, Gastroenterology.

[87]  B. Bacon,et al.  The pathology of hepatic iron overload: A free radical‐Mediated Process? , 1990, Hepatology.

[88]  S. Green Nuclear receptors and chemical carcinogenesis. , 1992, Trends in pharmacological sciences.

[89]  T. Watanabe,et al.  Compartmentation of dicarboxylic acid beta-oxidation in rat liver: importance of peroxisomes in the metabolism of dicarboxylic acids. , 1989, Biochimica et biophysica acta.

[90]  R. Roeder,et al.  The helix-loop-helix/leucine repeat transcription factor USF can be functionally regulated in a redox-dependent manner. , 1992, The Journal of biological chemistry.

[91]  J. Fernandes The Glycogen-Storage Diseases , 1990 .

[92]  F. Roels,et al.  Hepatocellular peroxisomes in human alcoholic and drug‐induced hepatitis: A quantitative study , 1991, Hepatology.

[93]  J. I. Pedersen,et al.  Metabolic aspects of peroxisomal β-oxidation , 1991 .

[94]  B. Halliwell,et al.  Oxygen toxicity, oxygen radicals, transition metals and disease. , 1984, The Biochemical journal.

[95]  R. Cattley,et al.  Possible Mechanisms in Hepatocarcinogensis by the Peroxisome Proliferator Di(2-Ethylhexyl)Phthalate , 1989 .

[96]  J. Wands,et al.  p53 mutation in hepatocellular carcinoma after aflatoxin exposure , 1991, The Lancet.

[97]  R. Jirtle,et al.  Induction of sister chromatid exchange and micronuclei in primary cultures of rat and human hepatocytes by the peroxisome proliferator, Wy-14,643. , 1993, Mutation research.

[98]  F. Iber,et al.  Hepatology: A Textbook of Liver Disease , 1983 .

[99]  Gary M Williams,et al.  Dose-response relationships of hepatic acyl-CoA oxidase and catalase activity and livermitogenesis induced by the peroxisome proliferator ciprofibrate in C57BL6N and BALBc mice , 1992 .

[100]  E. Farber Hepatocyte proliferation in stepwise development of experimental liver cell cancer , 1991, Digestive diseases and sciences.

[101]  D. Mayer,et al.  Hepatocellular glycogenosis and related pattern of enzymatic changes during hepatocarcinogenesis. , 1984, Advances in enzyme regulation.

[102]  R. Schulte‐Hermann,et al.  Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. , 1991, Cancer research.

[103]  J. Bar-Tana,et al.  The effect of bezafibrate and long-chain fatty acids on peroxisomal activities in cultured rat hepatocytes. , 1985, Biochimica et biophysica acta.

[104]  W. Jones,et al.  The effect of peroxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. , 1987, Drug metabolism reviews.

[105]  F. Chisari,et al.  Cellular and Molecular Mechanisms of Hepatocarcinogenesis , 1992, Seminars in liver disease.

[106]  T. Ono,et al.  Immunohistochemical distribution of hepatic fatty acid-binding protein in rat and human alimentary tract. , 1988, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[107]  W. Fleig,et al.  Hepatocellular carcinoma in type I glycogen storage disease , 1988, Hepatology.

[108]  E. Lock,et al.  Biochemical mechanisms of induction of hepatic peroxisome proliferation. , 1989, Annual review of pharmacology and toxicology.

[109]  C. Elcombe,et al.  Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators. , 1991, The Biochemical journal.

[110]  A. Kissebah,et al.  Mechanism of oestrogen and progesterone effects on lipid and carbohydrate metabolism: alteration in the insulin: glucagon molar ratio and hepatic enzyme activity , 1977, European journal of clinical investigation.

[111]  P. Eckl,et al.  Genotoxic effects of selected peroxisome proliferators. , 1993, Mutation research.

[112]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[113]  B. Brown,et al.  Hepatorenal glycogenosis (type I glycogenosis) and carcinoma of the liver. , 1969, The Journal of pediatrics.

[114]  S. Green Receptor-mediated mechanisms of peroxisome proliferators. , 1992, Biochemical pharmacology.

[115]  R. Infante,et al.  Increased uptake of fatty acids by the isolated rat liver after raising the fatty acid binding protein concentration with clofibrate. , 1978, Biochemical and biophysical research communications.